Helix BioPharma Appoints New Board Member and Corporate Secretary

Toronto, Ontario — May 13, 2026 — Leads & Copy — Helix BioPharma Corp. (TSX:HBP, OTC PINK:HBPCD, FRANKFURT:HBP0), a clinical-stage oncology company, has announced the appointments of Zachary T. Stadnyk to its Board of Directors and Natalia L. Butterworth as Corporate Secretary, effective immediately.

Stadnyk, formerly TSX Life Sciences Lead and a biotech capital markets executive, brings over 15 years of experience in biotechnology, capital markets, and public company leadership. He has advised biotech issuers, boards, and institutional investors on public listings, capital formation, and strategic positioning, and has experience in public market execution. Stadnyk has led and supported over $100 million in institutional financings and contributed to strategic transactions, including the $435 million acquisition of The Supreme Cannabis Company by Canopy Growth. He has also advised public companies across the biotech, healthcare, and AI sectors.

Butterworth, based in British Columbia, is a corporate governance professional with over 15 years of experience supporting public and private companies in governance and regulatory compliance across multiple jurisdictions. Her experience spans the pharmaceutical, technology, and finance sectors. These appointments are expected to strengthen Helix’s Canadian capital markets and governance expertise as the company advances its capital markets strategy, including preparations for a planned Nasdaq listing through the Multijurisdictional Disclosure System (MJDS).

Thomas Mehrling, MD, PhD, Chief Executive Officer of Helix BioPharma, stated that strengthening capital markets and governance capabilities remains a key priority as Helix continues to execute its corporate and clinical development objectives. He added that Stadnyk brings a wealth of experience in biotechnology financing, public markets, and strategic transactions, while Butterworth adds strong governance and corporate secretarial expertise. Mehrling noted that these appointments come at an important time for Helix as the company finalizes the clinical protocol for L-DOS47 and actively prepares for a Nasdaq listing under the MJDS, including ongoing audit, governance, and capital markets readiness initiatives.

Stadnyk stated that he is excited to join Helix at a pivotal stage in its development. He believes that the company’s approach to addressing the tumor microenvironment and its path toward a Nasdaq listing creates a compelling opportunity. He looks forward to supporting the team in advancing its capital markets strategy and unlocking value for its shareholders.

Helix BioPharma is also relocating its registered and records office from Toronto, Ontario, to Vancouver, British Columbia. The proposed move aligns with the strengthening of the company’s governance and capital markets infrastructure as Helix advances its Nasdaq uplisting strategy under the MJDS framework.

Helix BioPharma is an oncology company focused on near-term solutions for hard-to-treat cancers. Its pipeline is led by Tumor Defense Breaker™ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery. The company also advances two pre-IND candidates: (i) LEUMUNA™, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and (ii) GEMCEDA™, a first-in-class oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.

Helix is listed on TSX (HBP), OTC PINK (HBPCD), and FWB (HBP0).

Source: Helix BioPharma